What CLIScan Covers

Indexed. Non-indexed. Regional. Conference. All of it.

CLIScan monitors the broadest range of pharmacovigilance literature sources available, ensuring no safety-relevant publication goes undetected:

• Indexed Databases — PubMed, Embase, MEDLINE, Cochrane Library, and other major biomedical databases with automated query execution.
• Non-Indexed & Grey Literature — Preprints, institutional repositories, government reports, and publications not captured by standard database searches.
• Regional Journals — Local and regional medical journals published in non-English languages, covering markets where your products are authorized.
• Conference Abstracts — Major pharmacovigilance and therapeutic area conferences including DIA, ISPE, ICPE, and specialty medical meetings.
• Regulatory Alerts — Safety communications, Dear Healthcare Professional letters, and regulatory authority publications from FDA, EMA, MHRA, and others.

Why Literature Screening Matters

A missed article is a compliance failure waiting to happen.

Regulatory authorities require Marketing Authorization Holders to systematically monitor published literature for adverse event reports. EMA, FDA, and other agencies have issued clear guidance that literature screening is not optional — it is a regulatory obligation.

Most service providers rely on basic indexed database searches. CLIScan goes further — covering non-indexed sources, grey literature, and regional publications that traditional screening methods miss entirely.

• Full regulatory compliance with EMA and FDA literature monitoring requirements
• Non-indexed and grey literature coverage that competitors miss
• Automated, reproducible search strategies with complete audit trails
• Dedicated screening team with therapeutic area expertise
• Seamless integration with your ICSR processing workflow